Genetic Screening for Breast Cancer

[vc_row][vc_column][vc_column_text]Breast cancer is the most common type of cancer affecting women across the globe. Breast cancer is both genetically and histopathologically heterogenous, and the mechanisms underlying breast cancer development is largely unknown. (1)  Age is one of the significant risk factors in breast cancer. The incidence is increased by pregnancy but is permanently lowered by high parity. Breast cancer incidence is reduced by early first childbirth and the longer the women breastfeed the more they are protected against breast cancer. (2)  About 5% of breast cancers are found to have an underlying genetic cause and they follow autosomal dominant inheritance pattern. (3) Mutations in two specific tumor suppressor genes BRCA1 and BRCA2 have been implicated in 80% to 90% of all hereditary and breast and ovarian cancers. (4)  Ernst & Young report 2015 on cancer states that the low density of diagnostic facilities and absence of mass screening programmes is a major hurdle for timely diagnosis in India. (5) The breast cancer incidences in India have grown over the years and have steadily increased and as many as 100,000 new patients are being detected every year. (6)
Histologically, breast tumors can be classified on the basis of location of origin into ductal tumors, lobular tumors and other subtypes. Ductal tumors develop in breast ducts and represent 80% of tumors. Lobular tumors develop inside the lobes and they account for 10 to 15% of the cases, while other subtypes represent less than 10% of cases diagnosed per year.(7) Breast cancers are classified as:

Ductal Carcinoma in situ (DCIS): considered non-invasive or pre-invasive breast cancer. DCIS means the cells that line the ducts have become cancerous.

Lobular Carcinoma in situ (LCIS): cancer cells are seen growing in the lobules of the milk-producing glands of the breast, but they hardly grow through the wall of the lobules and hence are non-invasive.

When the DCIS and LCIS become invasive they are termed as Invasive Ductal Carcinoma (IDC) and Invasive Lobular Carcinoma (ILC) respectively. IDC is the most common kind of breast cancer.

Genetics of Breast Cancer
Those who inherit the risk of breast cancer are associated with the type of gene involved. For instance, mutations in the BRCA1 and BRCA2 genes are inherited in an autosomal dominant pattern (8).  Even though breast cancer is common in women, the mutated genes can be inherited either by mother or father. Mutations in some of the other genes such as PTEN, TP53, STK11, ATM, CDH1 and CHEK2 have also been found to increase the risk of breast cancer (9).

MedGenome Solutions
Apart from BRCA1 and BRCA2 gene analysis, MedGenome’s hereditary cancer mutation panel covers all the major genes implicated in and associated with breast cancer such as EPCAM, MLH1, MSH2, MSH6, and PMS2, PTEN, STK11 and TP53.  It is advisable that women with an abnormal breast cancer gene be screened twice a year as they have a much higher risk of developing cancer in the time between yearly screenings.(9)

References
1.Pharmocogenomics: An Introduction, edited by R Chakravarthy, 2006, ICFAI University Press.
2.Guy Bradley-Smith, Sally hope, Helen V. Firth, Jane A. Hurst, Oxford handbook of Genetics, OUP, 2011.
3.Peter S Harper, Practical Genetic Counselling, Edward Arnold Publishers Limited, 2004.
4.S. K. Singh, Cancer genetic and genomics, Surendra Publications, 2010.
5.Call for Action: Expanding cancer care in India, Ernst & Young, 2015.
6.Imran Ali, Waseem A. Wani and Kishwar Saleem, Cancer Scenario in India with Future Perspectives, Cancer Therapy Vol. 8, 56-70, 2011.
7.Bruna Karina Banin Hirata et al., Molecular markers for breast cancer: Prediction on tumor behavior, Disease Markers, Volume 2014.
8.http://ghr.nlm.nih.gov/condition/breast-cancer
http://www.breastcancer.org/risk/factors/genetics

[/vc_column_text][/vc_column][/vc_row]

Spina Bifida Birth Defect

[vc_row][vc_column][vc_column_text]Spina bifida is part of a group of birth defects called neural tube defects. An embryonic structure that eventually develops into the baby’s brain, spinal cord and surrounding tissues, the neural tube normally develops early in the pregnancy and closes by the 28th day after conception. In babies with spina bifida, a portion of the neural tube fails to develop or close properly, causing defects in the spinal cord and in the bones of the spine. Spina bifida, which literally means “cleft spine,” is characterized by the incomplete development of the brain, spinal cord, and/or meninges (the protective covering around the brain and spinal cord) (1,2) . Rates of the different types of spina bifida vary significantly by country from 0.1 to 5 per 1000 births. On average in developed countries it occurs in about 0.4 per 1000 births. In the United States it affected about 0.7 per 1000 births, and in India about 1.9 per 1000 births (3,4) .
Spina bifida most often occurs in three forms, categorised by severity of occurrence (2)

1. Type one: Myelomeningocele
Myelomeningocele is the most serious and more common of the two forms of cystic spina bifida. Here the cyst not only contains tissue and cerebro-spinal fluid but also nerves and part of the spinal cord. The spinal cord is damaged or not properly developed. As a result, there is always some paralysis and loss of sensation below the damaged region. The amount of disability is highly dependent on where the spina bifida is, and the amount of affected nerve tissue involved. Bladder and bowel problems occur in most people with myelomeningocele, as the nerves come from the bottom of the spinal cord, so are always below the lesion.

2. Type two: Meningocele
In this form, the sac contains meninges (tissues which cover the brain and spinal cord) and cerebro-spinal fluid, which bathes the central nervous system. Development of the spinal cord may be affected, but impairment is usually less severe than myelomeningocele. Meningocele is the least common form of spina bifida.

3. Spina Bifida Occulta (hidden form)
This is a mild form of spina bifida, which is very common. Estimates vary but between 5% and 10% of people globally may have spina bifida occulta. It must be emphasised that, for the vast majority of those affected, having spina bifida occulta is of no consequence whatsoever. Often people born with this, only become aware that they are afflicted with this, after having a back x-ray for an unrelated problem. However, for a few (about 1 in 1,000) there can be associated problems.

Genetics of Spina Bifida
Spina bifida is a complex condition likely caused by the interaction of multiple genetic and environmental factors. Changes in genes related to folate processing and genes involved in the development of the neural tube have been studied as potential risk factors for spina bifida. However the best studied gene of these is MTHFR, which provides instructions for making a protein that is involved in processing the vitamin folate (also called vitamin B9). A shortage (deficiency) of this vitamin is an established risk factor for neural tube defects (5).

Prenatal Diagnosis
Prenatal diagnosis is most commonly carried out by screening methods such as second trimester (16-18 weeks of gestation) maternal serum alpha fetoprotein (MSAFP) screening and fetal ultrasound. The MSAFP screen measures the level of a protein called alpha-fetoprotein (AFP), which is made naturally by the fetus and placenta. During pregnancy, a small amount of AFP normally crosses the placenta and enters the mother’s bloodstream. If abnormally high levels of this protein appear in the mother’s bloodstream, it may indicate that the fetus has an “open” (not skin-covered) neural tube defect. The MSAFP test, however, is not specific for spina bifida and requires correct gestational dates to be most accurate; it cannot definitively determine that there is a problem with the fetus. Amniocentesis may also be used to diagnose spina bifida. Although amniocentesis cannot reveal the severity of spina bifida, finding high levels of AFP and other proteins may indicate that the disorder is present (1).

Postnatal Diagnosis
Mild cases of spina bifida (occulta, closed) not diagnosed during prenatal testing may be detected postnatally by plain film X-ray examination. Individuals with the more severe forms of spina bifida often have muscle weakness in their feet, hips, and legs that result in deformities that may be present at birth. Doctors may use magnetic resonance imaging (MRI) or a computed tomography (CT) scan to get a clearer view of the spinal cord and vertebrae. If hydrocephalus is suspected, the doctor may request a CT scan and/or X-ray of the skull to look for extra cerebrospinal fluid inside the brain(1).

REFERENCES:
1.http://www.ninds.nih.gov/disorders/spina_bifida/detail_spina_bifida.htm
2.http://www.cdc.gov/ncbddd/spinabifida/facts.html
3.Bhide, P; Sagoo, GS; Moorthie, S; Burton, H; Kar, A (July 2013). “Systematic review of birth prevalence of neural tube defects in India.”. Birth defects research. Part A, Clinical and molecular teratology 97 (7): 437–43.
4.Kondo, A; Kamihira, O; Ozawa, H (January 2009). “Neural tube defects: prevalence, etiology and prevention.”. International journal of urology: official journal of the Japanese Urological Association 16 (1): 49–57.
5.http://ghr.nlm.nih.gov/condition/spina-bifida[/vc_column_text][/vc_column][/vc_row]

Genetics of Lung Cancer

[vc_row][vc_column][vc_column_text]Lung cancer is the most common cause of death from cancer worldwide, estimated to be responsible for nearly one in five (1.59 million deaths, 19.4% of the total). There are estimated to be 1.8 million new cases in 2012 (12.9% of the total), 58% of which occurred in the less developed regions. Because of its high fatality (the overall ratio of mortality to incidence is 0.87) and the relative lack of variability in survival in different world regions, the geographical patterns in mortality closely follow those in incidence (1,2).. Cancer is neither rare anywhere in the world, nor mainly confined to developed countries. Striking differences in the patterns of cancer from region to region are observed. As opposed to the 5 years survival of 52% in all cancers, the lung cancer survival rates continue to be poor (3).

In India, approximately 63,000 new lung cancer cases are reported each year. One of the major contributors to lung cancer is believed to be tobacco use and this is hence said to be a smoker’s disease. However, a significant number of patients with lung cancer have no history of smoking. Major gender, clinico-pathological, and molecular differences in lung cancers arising in never-smokers strongly suggest a disease distinct from the more common tobacco-associated forms of lung cancer (3).

Genetics of Lung Cancer

Lung cancer is comprised of two main histologic subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Subsets of NSCLC may be characterized by recurrent driver mutations in multiple oncogenes like ALK, BRAF, EGFR, HER2, MET , KRAS, NRAS and PIK3CA among others(4).
Specialized molecular and genetic testing for these kinds of cancer would prove to be very useful in detection and accurate treatment.
In general, hereditary lung cancer occurs more frequently in women, non smokers, and those with early onset lung cancer. Overall, it has been estimated that 1.7% of lung cancers up to the age of 68 are hereditary. Trend analysis reveals that patients of NSCLC, especially lung adenocarcinoma, are more likely to have a history of lung cancer than those with SCLC. Also people with a BRCA2 mutation have a higher risk than others, of developing lung cancer (5).

MedGenome’s Solutions:

MedGenome, a provider of clinical genomics solutions for personalized healthcare, offers comprehensive genetic diagnostic solutions for early detection of lung cancer. The solutions provided range from single gene testing for EGFR to testing a panel of genes (oncogenes and tumor suppressor genes) implicated in the onset of the disease.
Our Hereditary Cancer panel covers all the major genes linked to lung cancer. Early detection of cancer is the most important step in ensuring a favorable prognosis, and timely surgical intervention can reduce the risk of developing cancer by up to 85%.

REFERENCES:

1.http://globocan.iarc.fr/old/FactSheets/cancers/lung-new.asp
2.Behera, D. “Epidemiology of lung cancer–Global and Indian perspective.”Journal, Indian Academy of Clinical Medicine 13.2 (2012).
3.Noronha V, Dikshit R, Raut N, Joshi A, Pramesh C S, George K, Agarwal J P, Munshi A, Prabhash K. Epidemiology of lung cancer in India: Focus on the differences between non-smokers and smokers: A single-centre experience. Indian J Cancer 2012;49:74-81
4.Lovly, C., L. Horn, W. Pao. 2014. Molecular Profiling of Lung Cancer. My Cancer Genomehttp://www.mycancergenome.org/content/disease/lung-cancer/ (Updated March 31).
5.http://lungcancer.about.com/od/causesoflungcance1/a/famhxlungca.htm

[/vc_column_text][/vc_column][/vc_row]

World Immunization Day

[vc_row][vc_column][vc_column_text]Every year, 10th November is celebrated as World Immunization Day. According to the WHO, immunization prevents between 2 and 3 million deaths every year and now protects children not only against diseases for which vaccines have been available for many years, such as Diphtheria, Tetanus, Polio and Measles, but also against diseases such as Pneumonia and Rotavirus Diarrhoea, two of the biggest killers of children under age of five.

World Immunization Day is observed with the aim of highlighting vaccination as a low-tech, cost effective, high impact solution to preventing illness and disease in individuals of all ages. Vaccinations prevent susceptibility to illnesses which can result in serious complications and even death. If exposure to a disease occurs in a community, there is little to no risk of an epidemic if people have been immunized.

Recent advances in medical science have resulted in enhanced protection bestowed by vaccination. Some diseases that once killed thousands of children, have been eliminated completely and others are close to extinction– primarily due to safe and effective vaccines. Polio is a prime example of the great impact that vaccines have had in India. Polio was once India’s most-feared disease, causing death and paralysis across the country, but today, thanks to vaccination, as of 2014, India has been declared polio-free by the WHO, and has been removed from the list of endemic countries. Another example of the benefits of vaccination is the eradication of smallpox worldwide, because of which immunization against the disease is no longer a necessity. Regular and effective immunization may be able to ensure that many such diseases the plague may be eradicated soon.

Even though some diseases, such as polio, rarely affect people in developed nations, all of the recommended childhood immunizations and booster vaccines are still needed. Travellers may inadvertently bring these diseases into developed nations and infect people who have not been immunized. Without the protection via immunizations, these diseases may quickly spread through the population, causing epidemics. The same is true the other way wherein a traveller is entering a new country and immunization can help fight the common disease agents at the destination. Non-immunized people living in healthy conditions are not protected from disease. The immune system can fight a disease better and faster if the individual has had the infection before or has been immunized.

Some vaccine-preventable diseases can result in prolonged disabilities and can take a financial toll because of lost time at work, medical bills or long-term disability care. In contrast, getting vaccinated against these diseases is a good investment and usually covered by insurance.

A small number of people may be susceptible to diseases, such as those with impaired immune systems. These people may not be able to get vaccinations or may not develop immunity even after having been vaccinated. Their only protection against certain diseases is for others to get vaccinated so the illnesses are less common. Vaccines are only given to children after a long and careful review by scientists, doctors, and healthcare professionals. The benefits of vaccination cannot be emphasized enough, and it is safe to say the discomfort or pain caused by the side effects of the vaccine pale in comparison to the tremendous pain and illness caused by the diseases that these vaccines prevent.

[/vc_column_text][/vc_column][/vc_row]

Test Menu

Genetic Counselling

Microsites

Collaterals

Contact Us